ADRX · ADARx Pharmaceuticals, Inc.

🧪 Trial & FDA Catalysts

• Jan 2027 · Phase 1 · Recruiting · Phase 1 Study of ADX-626 in Healthy Participants
  Registry primary completion date, not a results date
• Nov 2027 · Phase 3 · Recruiting · STOP-HAE: A Phase 3 Study of ADX-324 in HAE
  Registry primary completion date, not a results date
• Dec 2027 · Phase 1/2 · Active Trial · Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Pa
  Registry primary completion date, not a results date
• Mar 2028 · Phase 1/2 · Recruiting · Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturna
  Registry primary completion date, not a results date
• Jul 2028 · Phase 2 · Recruiting · Chinese Adults With Kidney Disease
  Registry primary completion date, not a results date
• Dec 2028 · Phase 2 · Recruiting · Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
  Registry primary completion date, not a results date

📊 Drug Pipeline

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ADRX holds $427.3M in cash and short-term investments and burns about $22.1M/quarter from operations, an estimated runway of 58 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 8 · Low

• Cash runway 58 months
• S-1 registration (Sep 2026) +8

Recent financing filings on SEC EDGAR:

• Sep 28, 2026 · Registered direct / best-efforts offering, $446M · 424B4
• Sep 28, 2026 · Private placement (8-K Item 3.02) · 8-K
• Sep 4, 2026 · S-1 registration · S-1

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADRX files for a raise →